Table 1 Patient demographics and clinical characteristics (n = 423)

From: Determinants of COVID-19 disease severity in patients with cancer

Characteristic

No. (%)

Age (years)

 

 <18

7 (2)

 18–29

11 (3)

 30–39

19 (4)

 40–49

51 (12)

 50–59

101 (24)

 60–69

134 (32)

 ≥70

100 (24)

Sex

 

 Male

212 (50)

 Female

211 (50)

Race

 

 White

263 (62)

 Black

68 (16)

 Asian

36 (9)

 Other

56 (13)

Body mass index (BMI, kg/m2)

 

 <18.5 (underweight)

13 (3)

 18.5–24.9 (normal)

135 (32)

 25.0–29.9 (overweight)

146 (35)

 30.0–39.9 (obese)

109 (26)

 ≥40 (severely obese)

20 (5)

Smoking status

 

 Current

10 (2)

 Former

157 (37)

 Never

249 (59)

 Unknown

7 (2)

Underlying cancera

 

 Hematologic

 

  Leukemia

32 (8)

  Lymphoma

48 (11)

  Myeloma

22 (5)

 Solid tumor

 

  Breast

86 (20)

  Colorectal

37 (9)

  Lung

35 (8)

  Prostate

26 (6)

 Other

137 (32)

Metastatic disease

238 (56)

Major surgery (30 d)b

31 (7)

Asthma

43 (10)

COPD

29 (7)

Diabetes

84 (20)

Cardiac dysfunctionc

84 (20)

Chronic kidney disease

36 (9)

Hypertension

214 (51)

Systemic chemotherapy (within 30 d)d

191 (45)

Chronic corticosteroide

66 (16)

Chronic lymphopeniaf

9 (2)

ICIg

31 (7)

Symptoms at onset

 

 Fever

331 (78)

 Shortness of breath

186 (44)

 Cough

347 (82)

 Diarrhea

109 (26)

Outcomes (30 d)

 

 Hospitalization status

 

  Not admitted

243 (57)

  Admitted

168 (40)

  Already hospitalized

12 (3)

 Oxygen requirementsh

 

  Nonei

279 (66)

  Low-flow oxygen

57 (13)

  High-flow oxygenj

47 (11)

  Mechanical ventilation

40 (9)

 Death

51 (12)

  1. COPD, chronic obstructive pulmonary disease.
  2. a In patients with multiple malignancies, the most active and recently treated malignancy was used to define the underlying cancer.
  3. b Defined as any surgical procedure requiring general anesthesia.
  4. c Heart failure, myocardial infarction, valvular replacement or cardiomyopathy.
  5. d Systemic, parenteral chemotherapy.
  6. e Corticosteroids (equivalent of prednisone 20 mg or higher) for at least 10 d.
  7. f Absolute lymphocyte count <500 per microliter over five previous consecutive measurements.
  8. g ICI therapy consisted of the following, given within 90 d: pembrolizumab (18), nivolumab (5), atezolizumab (3), avelumab (1), durvalumab (1), ipilimumab (1), nivolumab + ipilimumab (1) and pembrolizumab followed by nivolumab (1).
  9. h Highest oxygen requirement over 30 d is shown.
  10. i Note: two patients had chronic tracheostomy because of prior medical issues but did not require supplemental oxygen during COVID-19 infection.
  11. j Includes the following oxygen delivery routes: non-rebreather mask, high-flow nasal oxygen and bilevel positive airway pressure.